<p>Collegium Pharmaceutical, Inc. (NASDAQ:COLL - 获取免费报告) 在 7 月份看到了空头头寸的显著减少。截至 7 月 31 日，空头头寸总计为 6,220,000 股，较 7 月 15 日的 6,920,000 股减少了 10.1%。根据平均每日成交量为 544,200 股，目前的空头头寸比率为 11.4 天。公司约 19.6% 的股份被做空。</p>
<h2>Collegium Pharmaceutical 股票表现</h2>
<p>Collegium Pharmaceutical 股票在周五的午间交易中下跌了 0.22 美元，至 35.26 美元。该公司的交易量为 206,394 股，相比平均交易量 468,546 股有所下降。该公司的速动比率为 1.14，流动比率为 1.21，负债与权益比率为 1.98。 Collegium Pharmaceutical 的 52 周最低价为 20.95 美元，52 周最高价为 40.95 美元。该公司的 50 天移动平均价为 33.44 美元，200 天移动平均价为 34.91 美元。该公司的市值为 11.5 亿美元，市盈率为 14.69，贝塔系数为 0.93。</p>
<p>Collegium Pharmaceutical (NASDAQ:COLL - 获取免费报告) 最近公布了其截至 8 月 8 日的季度财报。这家专业药品公司报告称，该季度每股收益为 1.62 美元，超过了 1.40 美元的共识预期 0.22 美元。该公司在该季度实现了 1.4528 亿美元的收入，超过了分析师对 1.4394 亿美元的预期。 Collegium Pharmaceutical 的净利润率为 16.46%，净资产收益率为 104.98%。公司的季度收入较去年同期增长了 7.2%。去年同期，公司每股收益为 1.13 美元。卖方分析师平均预计，Collegium Pharmaceutical 今年财政年度的每股收益将达到 5.73 美元。</p>
<h2>内部人士的交易</h2>
<p>据悉，首席财务官 Colleen Tupper 于 5 月 28 日星期二以 34.21 美元的平均价格出售了公司的 19,710 股股票。该股票的交易额为 674,279.10 美元。此次交易后，首席财务官现在持有公司股票 130,845 股，价值 4,476,207.45 美元。该交易已在证券交易委员会的一份文件中披露，可以通过此超链接访问。另外，执行副总裁 Scott Dreyer 于 5 月 24 日星期五以 33.98 美元的平均价格出售了公司的 56,807 股股票。这些股票的总价值为 1,930,301.86 美元。交易完成后，该执行副总裁现在直接持有公司股票 105,902 股，价值 3,598,549.96 美元。该销售交易已在 SEC 的一份文件中披露，可在此链接处查看。此外，首席财务官 Colleen Tupper 还在 5 月 28 日星期二的交易中以 34.21 美元的平均价格出售了公司的 19,710 股股票。该股票的交易额为 674,279.10 美元。交易完成后，首席财务官现在直接持有公司股票 130,845 股，价值 4,476,207.45 美元。此次交易的披露信息可在此处找到。公司的 3.98% 股份由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近增加或减少了他们在该公司的持股。Gladius Capital Management LP 在第二季度以约 32,000 美元的价格获得了 Collegium Pharmaceutical 的新头寸。Principal Securities Inc.在第四季度以约 40,000 美元的价格获得了 Collegium Pharmaceutical 的新头寸。nVerses Capital LLC 在第二季度将其在 Collegium Pharmaceutical 的持股增加了 1,600.0%。nVerses Capital LLC 现在拥有该专业药品公司的 1,700 股股票，价值 55,000 美元，较上一季度增加了 1,600 股。Assetmark Inc.在第四季度将其在 Collegium Pharmaceutical 的持股增加了 25.5%。Assetmark Inc.现在拥有该专业药品公司的 5,445 股股票，价值 168,000 美元，较上一季度增加了 1,108 股。最后，Sheaff Brock Investment Advisors LLC 在第一季度购买了 Collegium Pharmaceutical 的新股份，价值约 204,000 美元。</p>
<h2>分析师的升级和降级</h2>
<p>一些研究公司最近发布了关于 COLL 的报告。Truist Financial 将 Collegium Pharmaceutical 的股票价格目标从 40.00 美元上调至 42.00 美元，并在 8 月 9 日的研究报告中给予该股票 “买入” 评级。Jefferies Financial Group 将 Collegium Pharmaceutical 的股票评级从 “持有” 上调至 “买入”，并将公司的目标股价从 41.00 美元上调至 44.00 美元，该研究报告发布于 6 月 7 日。StockNews.com 将 Collegium Pharmaceutical 的股票评级从 “买入” 上调至 “强烈买入”，该研究报告发布于 8 月 12 日。Piper Sandler 重申了对 Collegium Pharmaceutical 股票的 “中性” 评级，并将目标股价设定为 37.00 美元（从 39.00 美元下调），该研究报告发布于 8 月 9 日。最后，HC Wainwright 将 Collegium Pharmaceutical 的股票评级从 “中性” 上调至 “买入”，并为该公司设定了 47.00 美元的目标股价，该研究报告发布于 7 月 30 日。两位研究分析师对该股票给予持有评级，三位分析师给予买入评级，一位分析师给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “中等买入”，平均目标股价为 42.00 美元。</p>
<p><strong>阅读我们对 Collegium Pharmaceutical 的最新股票分析</strong></p>
<h2>Collegium Pharmaceutical 公司简介（获取免费报告）</h2>
<p>Collegium Pharmaceutical，Inc 是一家专业的制药公司，致力于开发和商业化用于疼痛管理的药物。其产品组合包括 Xtampza ER，这是一种滥用防止、长效缓释的盐酸羟考酮口服制剂，用于治疗需要每天、全天候、长期使用阿片类药物的严重疼痛；Nucynta ER 和 Nucynta IR，分别是盐酸他芬太醇的缓释和即时释放制剂，适用于急性、严重和持续性疼痛的管理；Belbuca，一种含有丁丙诺啡的颊膜片剂；以及 Symproic，一种纳尔德美定的口服制剂，用于治疗慢性非癌症疼痛成人患者的阿片类药物引起的便秘。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们比 Collegium Pharmaceutical 更喜欢的股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>这家小市值财富管理公司股票可能带来巨大回报</li>
<li>什么是二次公开发行？投资者需要了解的事项</li>
<li>Bumble 的估值创历史新低，它的命运能否改变？</li>
<li>能源和石油股票解析</li>
<li>MarketBeat 周评 - 8/12 - 8/16</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 紧急：您的财务自由正受到威胁 - 立即行动！（来自 Anthem Gold Group）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTk0"/></p>
<h2>现在是否值得投资$1,000 在 Collegium Pharmaceutical？</h2>
<p>在考虑 Collegium Pharmaceutical 之前，您需要听到这个消息。</p>
<p>MarketBeat 跟踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Collegium Pharmaceutical 并不在其中。</p>
<p>尽管 Collegium Pharmaceutical 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Collegium制药

<p>Collegium 制药公司在 7 月份经历了显著的空头头寸下降，下降了 10.1%，截至 7 月 31 日，空头头寸总数为 6,220,000 股，占总股本的 19.6%。该公司的平均每日交易量为 544,200 股，导致了一个 11.4 天的交易天数覆盖率。在最新的财报中，Collegium 每股收益为 0.62 美元，超过了预期，并录得了 2,800 万美元的营收，略低于预期。此外，还注意到了一些内部交易和机构持股的变化</p>

<p>Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 6,220,000 shares, a decrease of 10.1% from the July 15th total of 6,920,000 shares. Based on an average daily volume of 544,200 shares, the short-interest ratio is presently 11.4 days. Approximately 19.6% of the company's shares are sold short.</p>
<div class="lb-trans"><p>Collegium Pharmaceutical, Inc. (NASDAQ:COLL - 获取免费报告) 在 7 月份看到了空头头寸的显著减少。截至 7 月 31 日，空头头寸总计为 6,220,000 股，较 7 月 15 日的 6,920,000 股减少了 10.1%。根据平均每日成交量为 544,200 股，目前的空头头寸比率为 11.4 天。公司约 19.6% 的股份被做空。</p>
</div><h2>Collegium Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>Collegium Pharmaceutical 股票表现</h2>
</div><p>Collegium Pharmaceutical stock traded down $0.22 during mid-day trading on Friday, reaching $35.26. The company had a trading volume of 206,394 shares, compared to its average volume of 468,546. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. Collegium Pharmaceutical has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a 50 day moving average of $33.44 and a 200-day moving average of $34.91. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of 14.69 and a beta of 0.93.</p>
<div class="lb-trans"><p>Collegium Pharmaceutical 股票在周五的午间交易中下跌了 0.22 美元，至 35.26 美元。该公司的交易量为 206,394 股，相比平均交易量 468,546 股有所下降。该公司的速动比率为 1.14，流动比率为 1.21，负债与权益比率为 1.98。 Collegium Pharmaceutical 的 52 周最低价为 20.95 美元，52 周最高价为 40.95 美元。该公司的 50 天移动平均价为 33.44 美元，200 天移动平均价为 34.91 美元。该公司的市值为 11.5 亿美元，市盈率为 14.69，贝塔系数为 0.93。</p>
</div><p>Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million during the quarter, compared to analysts' expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.13 EPS. On average, sell-side analysts expect that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Collegium Pharmaceutical (NASDAQ:COLL - 获取免费报告) 最近公布了其截至 8 月 8 日的季度财报。这家专业药品公司报告称，该季度每股收益为 1.62 美元，超过了 1.40 美元的共识预期 0.22 美元。该公司在该季度实现了 1.4528 亿美元的收入，超过了分析师对 1.4394 亿美元的预期。 Collegium Pharmaceutical 的净利润率为 16.46%，净资产收益率为 104.98%。公司的季度收入较去年同期增长了 7.2%。去年同期，公司每股收益为 1.13 美元。卖方分析师平均预计，Collegium Pharmaceutical 今年财政年度的每股收益将达到 5.73 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士的交易</h2>
</div><p>In other news, CFO Colleen Tupper sold 19,710 shares of the company's stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company's stock, valued at $4,476,207.45. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the transaction, the executive vice president now directly owns 105,902 shares of the company's stock, valued at $3,598,549.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm's stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares of the company's stock, valued at $4,476,207.45. The disclosure for this sale can be found here. 3.98% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>据悉，首席财务官 Colleen Tupper 于 5 月 28 日星期二以 34.21 美元的平均价格出售了公司的 19,710 股股票。该股票的交易额为 674,279.10 美元。此次交易后，首席财务官现在持有公司股票 130,845 股，价值 4,476,207.45 美元。该交易已在证券交易委员会的一份文件中披露，可以通过此超链接访问。另外，执行副总裁 Scott Dreyer 于 5 月 24 日星期五以 33.98 美元的平均价格出售了公司的 56,807 股股票。这些股票的总价值为 1,930,301.86 美元。交易完成后，该执行副总裁现在直接持有公司股票 105,902 股，价值 3,598,549.96 美元。该销售交易已在 SEC 的一份文件中披露，可在此链接处查看。此外，首席财务官 Colleen Tupper 还在 5 月 28 日星期二的交易中以 34.21 美元的平均价格出售了公司的 19,710 股股票。该股票的交易额为 674,279.10 美元。交易完成后，首席财务官现在直接持有公司股票 130,845 股，价值 4,476,207.45 美元。此次交易的披露信息可在此处找到。公司的 3.98% 股份由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Gladius Capital Management LP acquired a new position in Collegium Pharmaceutical in the 2nd quarter valued at about $32,000. Principal Securities Inc. acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at about $40,000. nVerses Capital LLC grew its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. Assetmark Inc. grew its stake in Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company's stock valued at $168,000 after buying an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new stake in Collegium Pharmaceutical in the 1st quarter valued at about $204,000.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了他们在该公司的持股。Gladius Capital Management LP 在第二季度以约 32,000 美元的价格获得了 Collegium Pharmaceutical 的新头寸。Principal Securities Inc.在第四季度以约 40,000 美元的价格获得了 Collegium Pharmaceutical 的新头寸。nVerses Capital LLC 在第二季度将其在 Collegium Pharmaceutical 的持股增加了 1,600.0%。nVerses Capital LLC 现在拥有该专业药品公司的 1,700 股股票，价值 55,000 美元，较上一季度增加了 1,600 股。Assetmark Inc.在第四季度将其在 Collegium Pharmaceutical 的持股增加了 25.5%。Assetmark Inc.现在拥有该专业药品公司的 5,445 股股票，价值 168,000 美元，较上一季度增加了 1,108 股。最后，Sheaff Brock Investment Advisors LLC 在第一季度购买了 Collegium Pharmaceutical 的新股份，价值约 204,000 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>Several research firms recently issued reports on COLL. Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, August 9th. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price objective for the company from $41.00 to $44.00 in a research report on Friday, June 7th. StockNews.com raised shares of Collegium Pharmaceutical from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, August 12th. Piper Sandler reissued a &#34;neutral&#34; rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, HC Wainwright raised shares of Collegium Pharmaceutical from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $47.00 target price for the company in a research note on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $42.00.</p>
<div class="lb-trans"><p>一些研究公司最近发布了关于 COLL 的报告。Truist Financial 将 Collegium Pharmaceutical 的股票价格目标从 40.00 美元上调至 42.00 美元，并在 8 月 9 日的研究报告中给予该股票 “买入” 评级。Jefferies Financial Group 将 Collegium Pharmaceutical 的股票评级从 “持有” 上调至 “买入”，并将公司的目标股价从 41.00 美元上调至 44.00 美元，该研究报告发布于 6 月 7 日。StockNews.com 将 Collegium Pharmaceutical 的股票评级从 “买入” 上调至 “强烈买入”，该研究报告发布于 8 月 12 日。Piper Sandler 重申了对 Collegium Pharmaceutical 股票的 “中性” 评级，并将目标股价设定为 37.00 美元（从 39.00 美元下调），该研究报告发布于 8 月 9 日。最后，HC Wainwright 将 Collegium Pharmaceutical 的股票评级从 “中性” 上调至 “买入”，并为该公司设定了 47.00 美元的目标股价，该研究报告发布于 7 月 30 日。两位研究分析师对该股票给予持有评级，三位分析师给予买入评级，一位分析师给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “中等买入”，平均目标股价为 42.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Collegium Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Collegium Pharmaceutical 的最新股票分析</strong></p>
</div><h2>Collegium Pharmaceutical Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Collegium Pharmaceutical 公司简介（获取免费报告）</h2>
</div><p>Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.</p>
<div class="lb-trans"><p>Collegium Pharmaceutical，Inc 是一家专业的制药公司，致力于开发和商业化用于疼痛管理的药物。其产品组合包括 Xtampza ER，这是一种滥用防止、长效缓释的盐酸羟考酮口服制剂，用于治疗需要每天、全天候、长期使用阿片类药物的严重疼痛；Nucynta ER 和 Nucynta IR，分别是盐酸他芬太醇的缓释和即时释放制剂，适用于急性、严重和持续性疼痛的管理；Belbuca，一种含有丁丙诺啡的颊膜片剂；以及 Symproic，一种纳尔德美定的口服制剂，用于治疗慢性非癌症疼痛成人患者的阿片类药物引起的便秘。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Collegium Pharmaceutical</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>This Small Cap Wealth Management Stock Could Provide Big Returns</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Bumble's Valuation Hits an All-Time Low, Can Its Fortunes Change?</li>
<li>Energy and Oil Stocks Explained</li>
<li>MarketBeat Week in Review – 8/12 - 8/16</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>五只我们比 Collegium Pharmaceutical 更喜欢的股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>这家小市值财富管理公司股票可能带来巨大回报</li>
<li>什么是二次公开发行？投资者需要了解的事项</li>
<li>Bumble 的估值创历史新低，它的命运能否改变？</li>
<li>能源和石油股票解析</li>
<li>MarketBeat 周评 - 8/12 - 8/16</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ URGENT: Your Financial Freedom is Under Attack – Act Now! (From Anthem Gold Group)(Ad)</p>
<div class="lb-trans"><p>→ 紧急：您的财务自由正受到威胁 - 立即行动！（来自 Anthem Gold Group）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTk0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9194&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Collegium Pharmaceutical right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Collegium Pharmaceutical？</h2>
</div><p>Before you consider Collegium Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Collegium Pharmaceutical 之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Collegium Pharmaceutical 并不在其中。</p>
</div><p>While Collegium Pharmaceutical currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Collegium Pharmaceutical 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Collegium 制药公司（纳斯达克股票代码：COLL）空头头寸最新情况